Infectious complications in children with acute lymphoblastic leukemia treated in low-middle-income countries

Expert Rev Hematol. 2015 Oct;8(5):627-45. doi: 10.1586/17474086.2015.1071186. Epub 2015 Jul 27.

Abstract

Infections are the most important cause of morbidity and mortality in children treated for acute lymphoblastic leukemia (ALL). The rates of infection-associated mortality are up to 10-times higher in low- and middle-income countries (LMIC) than in high-income countries. The prevention, early recognition and management of infectious complications is especially challenging in LMIC because of disease and poverty-related factors, as well as the shortage of trained personnel, supplies, diagnostic tools and adequate organizational infrastructure. Children in LMIC with ALL, who are frequently underweight, are at increased risk of community-acquired pathogens, nosocomial multidrug-resistant pathogens and opportunistic microorganisms. This review summarizes the challenges of managing the major categories of infections in children receiving treatment for ALL and provides updated practical recommendations for preventing and managing these infections in LMIC.

Keywords: childhood acute lymphoblastic leukemia; febrile neutropenia; immune suppression; infections; low- and middle-income countries.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Age Factors
  • Antibiotic Prophylaxis
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Child
  • Developing Countries
  • Disease Management
  • Febrile Neutropenia / diagnosis
  • Febrile Neutropenia / drug therapy
  • Febrile Neutropenia / etiology
  • Febrile Neutropenia / prevention & control
  • Humans
  • Infections / diagnosis
  • Infections / etiology*
  • Infections / therapy
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications*
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • Vaccines / administration & dosage

Substances

  • Vaccines